Nimbus can't offload psoriasis drug, rules US judge
MLex Summary: Nimbus Therapeutics may not encumber assets associated with a psoriasis drug to block Celgene from assigning its rights following a merger with Bristol-Myers Squibb, a judge ruled. US District Judge...To view the full article, register now.
Already a subscriber? Click here to view full article